Imara M&A

The Enliven Story 過 Discovery process rooted in validated biology, differentiated chemistry, and disciplined trial design Capital-efficient approach on high potential programs aiming to develop first-in-class or best- in-class candidates a ELVN-001 and ELVN-002 supported by preclinical evidence of an improved therapeutic index Multiple near-term milestones in lead programs targeting large and attractive markets Bo 8-8 Experienced team with a track record of inventing and developing multiple FDA-approved cancer therapies Supported by top tier healthcare investors and a strong balance sheet expected to provide cash runway into early 2026 LO 5

View entire presentation